Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HOLOGIC INCHOLX · Entity 12463 | Director | November 13, 2017 | November 15, 2017 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director | May 22, 2019 | May 23, 2019 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | June 01, 2019 | June 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HOLOGIC INC
Report date November 13, 2017 · Filed November 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,302 |
Last balance in matching sequence
After 2017-11-14 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2017-11-13 · Exercise / conversion · Acquired 9,282 · Balance 33,092 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan. Row 2 · 2017-11-13 · Sale · Disposed 9,282 · Balance 23,810 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan. Row 3 · 2017-11-14 · Exercise / conversion · Acquired 3,492 · Balance 27,302 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.82 · Expires 2018-01-01 | Direct | 3,492 |
Reported balance
After 2017-11-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-11-13 · Exercise / conversion · Disposed 9,282 · Balance 3,492 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F3: This option became fully vested on January 1, 2008 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.82 · Expires 2018-01-01 | Direct | 0 |
Reported balance
After 2017-11-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-11-14 · Exercise / conversion · Disposed 3,492 · Balance 0 F1: Transaction pursuant to an existing rule 10b5-1 trading plan. F3: This option became fully vested on January 1, 2008 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to an existing rule 10b5-1 trading plan.
F2: Includes 3,260 shares subject to deferral pursuant to Issuer's Deferred Equity Plan.
F3: This option became fully vested on January 1, 2008
THERMO FISHER SCIENTIFIC INC.
Report date May 22, 2019 · Filed May 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,706 |
Reported balance
After 2019-05-22 transaction · row 1
1 source rowRow 1 · 2019-05-22 · Grant · Acquired 718 · Balance 4,706 |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 3,638 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,638 F1: These shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust on May 6, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust on May 6, 2019.
VERTEX PHARMACEUTICALS INC / MA
Report date June 01, 2019 · Filed June 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $168.04 · Expires 2029-05-31 | Direct | 6,659 |
Reported balance
After 2019-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-01 · Grant · Acquired 6,659 · Balance 6,659 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $109.30 | $32,790.00 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · nonDerivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,465 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $109.30 (range $109.24 to $109.42). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $108.32 | $119,152.00 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · nonDerivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $108.32 (range $107.99 to $108.81). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,592 | $107.48 | $278,588.16 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,865 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $107.48 (range $106.93 to $107.92). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 808 | $106.42 | $85,987.36 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,457 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $106.42 (range $105.93 to $106.89). F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $34.32 | $171,600.00 |
DisclosureSEC source: 0001209191-14-061668 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0001209191-14-046024 · doc4.xml · derivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2016-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,800 | $95.26 | $457,248.00 |
DisclosureSEC source: 0001209191-14-046024 · doc4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $95.26 (range $94.80 to $95.65). Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $94.09 | $18,818.00 |
DisclosureSEC source: 0001209191-14-046024 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,065 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $94.09 (range $93.79 to $94.39). F3 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $34.32 | $171,600.00 |
DisclosureSEC source: 0001209191-14-046024 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2014 Filed Feb 13, 2015 22:04 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GiftCommon Stock | 4,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-006063 · form5.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,914 Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0001209191-14-040503 · doc4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 2,500 shares Expires 2016-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $75.00 | $187,500.00 |
DisclosureSEC source: 0001209191-14-040503 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms.Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,500 | $34.32 | $85,800.00 |
DisclosureSEC source: 0001209191-14-040503 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2014 Filed Jun 3, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-14-038672 · doc4.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2024-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 20, 2014 Filed May 22, 2014 21:02 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 1,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-018494 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,159 Read SEC document |
| April 09, 2014 Filed Apr 11, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option(right to buy) · Derivative | 2,500 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0001209191-14-027157 · doc4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 2,500 shares Expires 2016-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| April 09, 2014 Filed Apr 11, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $70.00 | $175,000.00 |
DisclosureSEC source: 0001209191-14-027157 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 09, 2014 Filed Apr 11, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,500 | $34.32 | $85,800.00 |
DisclosureSEC source: 0001209191-14-027157 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2013 Filed Jun 4, 2013 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-13-030499 · doc4.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2023-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 22, 2013 Filed May 24, 2013 20:33 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 1,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-018284 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,848 Read SEC document |
| May 07, 2013 Filed May 8, 2013 21:27 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 8,000 | $82.73 | $661,840.00 |
DisclosureSEC source: 0001127602-13-016166 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,109 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.69 to $82.77, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2013 Filed May 7, 2013 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $29.89 | $0.00 |
DisclosureSEC source: 0001209191-13-024590 · doc4.xml · derivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2019-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| May 03, 2013 Filed May 7, 2013 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0001209191-13-024590 · doc4.xml · derivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| May 03, 2013 Filed May 7, 2013 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 40,000 | $77.99 | $3,119,600.00 |
DisclosureSEC source: 0001209191-13-024590 · doc4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · price: Open market sales reported on this line occurred at a weighted average price of $77.99 (range $77.95 to $78.15). F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2013 Filed May 7, 2013 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $29.89 | $597,800.00 |
DisclosureSEC source: 0001209191-13-024590 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2013 Filed May 7, 2013 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $29.84 | $596,800.00 |
DisclosureSEC source: 0001209191-13-024590 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2012 Filed Nov 15, 2012 21:41 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,500 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001127602-12-030977 · form4.xml · derivative · entry 5 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2013-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option originally was to have vested in three equal annual installments beginning on May 24, 2007, but became fully exercisable on November 9, 2006, as a result of the Issuer's merger with Fisher Scientific International Inc. Read SEC document |
| November 13, 2012 Filed Nov 15, 2012 21:41 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,600 | $0.00 Strike: $43.37 | $0.00 |
DisclosureSEC source: 0001127602-12-030977 · form4.xml · derivative · entry 4 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,600 shares Expires 2013-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in three equal installments on November 9, 2007, 2008 and 2009. Read SEC document |
| November 13, 2012 Filed Nov 15, 2012 21:41 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 26,100 | $61.51 | $1,605,411.00 |
DisclosureSEC source: 0001127602-12-030977 · form4.xml · nonDerivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,109 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.46 to $61.57, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 13, 2012 Filed Nov 15, 2012 21:41 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 10,500 | $36.75 | $385,875.00 |
DisclosureSEC source: 0001127602-12-030977 · form4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2012 Filed Nov 15, 2012 21:41 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 15,600 | $43.37 | $676,572.00 |
DisclosureSEC source: 0001127602-12-030977 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2012 Filed Jun 1, 2012 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-12-031712 · doc4.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2022-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 23, 2012 Filed May 25, 2012 21:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-018316 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,109 Read SEC document |
| May 09, 2012 Filed May 11, 2012 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $28.40 | $0.00 |
DisclosureSEC source: 0001209191-12-027575 · doc4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| May 09, 2012 Filed May 11, 2012 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20,000 | $60.58 | $1,211,600.00 |
DisclosureSEC source: 0001209191-12-027575 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · price: Open market sales reported on this line occurred at a weighted average price of $60.58 (range $60.50 to $60.71). F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 09, 2012 Filed May 11, 2012 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $28.40 | $568,000.00 |
DisclosureSEC source: 0001209191-12-027575 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2012 Filed May 1, 2012 19:31 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001127602-12-015166 · form4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2012-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option originally was to have vested in three equal annual installments beginning on May 17, 2006, but became fully exercisable on November 9, 2006, as a result of the Issuer's merger with Fisher Scientific International Inc. Read SEC document |
| April 30, 2012 Filed May 1, 2012 19:31 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 7,500 | $55.22 | $414,150.00 |
DisclosureSEC source: 0001127602-12-015166 · form4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,657 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.21 to $55.23, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2012 Filed May 1, 2012 19:31 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 7,500 | $26.53 | $198,975.00 |
DisclosureSEC source: 0001127602-12-015166 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-11-032547 · doc4.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2021-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 25, 2011 Filed May 27, 2011 20:49 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 1,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-017772 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,657 Read SEC document |
| March 23, 2011 Filed Mar 24, 2011 17:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $44.47 | $0.00 |
DisclosureSEC source: 0001209191-11-019495 · doc4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2011-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2011 Filed Mar 24, 2011 17:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,235 | $46.08 | $333,388.80 |
DisclosureSEC source: 0001209191-11-019495 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · price: Open market sales reported on this line occurred at a weighted average price of $46.08 (range $46.07 to $46.11). F2 · price: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 23, 2011 Filed Mar 24, 2011 17:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $44.47 | $333,525.00 |
DisclosureSEC source: 0001209191-11-019495 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2011 Filed Mar 3, 2011 21:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $28.73 | $0.00 |
DisclosureSEC source: 0001127602-11-008761 · form4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2011-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in three equal installments on May 18, 2005, 2006, and 2007. Read SEC document |
| March 01, 2011 Filed Mar 3, 2011 21:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 7,500 | $56.35 | $422,625.00 |
DisclosureSEC source: 0001127602-11-008761 · form4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,709 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.35 to $56.38, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2011 Filed Mar 3, 2011 21:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Exercise / conversionCommon Stock | 7,500 | $28.73 | $215,475.00 |
DisclosureSEC source: 0001127602-11-008761 · form4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2010 Filed Oct 4, 2010 19:16 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantPhantom Stock Units · Derivative | 470.51 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-021904 · doc4.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,435.39 Underlying: Common Stock · 470.51 shares Expires not disclosed F1 · derivative.exercise_price: Convertible into Common Stock on a 1-for-1 basis. F2 · price: Represents stock units credited to the Reporting Person's account as of October 2, 2010, at a price of $47.82 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control. F2 · derivative.exercise_date: Represents stock units credited to the Reporting Person's account as of October 2, 2010, at a price of $47.82 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control. F2 · derivative.expiration_date: Represents stock units credited to the Reporting Person's account as of October 2, 2010, at a price of $47.82 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control. Read SEC document |
| July 03, 2010 Filed Jul 6, 2010 19:26 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantPhantom Stock Units · Derivative | 311.87 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-016721 · doc4.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,964.88 Underlying: Common Stock · 311.87 shares Expires not disclosed F1 · derivative.exercise_price: Convertible into Common Stock on a 1-for-1 basis. F2 · price: Represents stock units credited to the Reporting Person's account as of July 3, 2010, at a price of $47.58 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control. F2 · derivative.exercise_date: Represents stock units credited to the Reporting Person's account as of July 3, 2010, at a price of $47.58 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control. F2 · derivative.expiration_date: Represents stock units credited to the Reporting Person's account as of July 3, 2010, at a price of $47.58 per unit pursuant to the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Directors' retainers are deferred quarterly under the Plan as Common Stock units based on the closing price of the stock as of the quarter end. The shares are distributable as stock upon cessation of director service (for any reason) or a change of control. Read SEC document |
| June 01, 2010 Filed Jun 2, 2010 19:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000027 · edgar.xml · derivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.